Dr. Garry Ferroniis a bit of a legend. He is professor emeritus (retired) at the Northern Ontario School of Medicine and was a microbiology professor when I was a molecular biology student at Laurentian University. Most of my classmates and I were in awe of Ferroni.
His area of expertise is medical microbiology and infectious diseases. He has a PhD from the University of Waterloo and spent his career doing research and teaching at LU and NOSM.
At NOSM, he was the founding division head of medical sciences, as well as a professor, and he worked with colleagues in Sudbury and Thunder Bay to develop the infectious diseases curriculum for the medical program.
The Star reached out to Ferroni with some questions on COVID-19. Ever the helpful teacher, he was happy to oblige.
Q. In lay person terms, what is the novel coronavirus?
A. COVID-19 is caused by a virus officially named SARS-CoV-2, which stands for severe acute respiratory syndrome coronavirus 2. This virus is being referred to in the media as COVID-19 or novel coronavirus. It is the newest virus in a family of viruses called coronaviruses, so named because club-shaped protrusions from their surface give them a crown-like appearance.
Most of them infect animals such as bats, pigs and camels, but a few have managed to jump to humans.
In humans, they tend to cause mild upper respiratory tract infections diagnosed as the common cold. The exceptions are the coronaviruses that cause SARS, Middle East Respiratory Syndrome (MERS) and COVID-19. These coronaviruses are more adept at invading the lower respiratory tract where they can cause a very severe pneumonia.
Dr. Garry Ferroni is a retired professor from NOSM and Laurentian University. He taught microbiology and infectious diseases. In fact, he helped establish the curriculum for the medical school.supplied photo
Q. Do we know how the virus was transmitted from animal to human? How is it transmitted from person to person?
A. The assumption is the COVID-19 virus was transmitted from animal to human, and the animal often mentioned is the bat. There are some who suggest that animals called pangolins might be an intermediary host, which means the virus moved from an unknown animal to pangolins and then to humans.
The possibility that an exotic animal market in Wuhan, China, provided the opportunity for animal to human transmission has not been proven. At this point, the origin of the virus just isnt known. Studies of the sequence of the viruss genetic material (genome) relative to other coronavirus genomes do indicate the COVID-19 virus arose naturally as opposed to being created in a research laboratory.
It is likely that infected persons transmit the virus to other persons via respiratory droplets in their coughs and sneezes (such droplets might even be discharged by talking and deep breathing) and by direct contact, such as hand-shaking and hugging. It follows that infected persons would contaminate surfaces and objects via droplets and direct contact. If we touch or handle these and then touch our faces, we can introduce the virus into our bodies, the entry sites being the mouth, nose and eyes. Knowing how infectious agents are transmitted allows us to protect ourselves and our contacts.
Registered nurses Karen Hatton, left, and Theresa Murray stand inside a shelter associated with the drive-through option for coronavirus testing on Walford Road.Jim Moodie/Sudbury Star
Q. How long does the virus live on different surfaces, such as plastic, metal, produce?
A. Viruses can survive on surfaces for a limited period of time, but they cannot multiply. They must invade the cells of an appropriate organism to multiply. Not surprisingly, there is not a lot of information on the survival of the COVID-19 virus when it is outside of the human host.
Studies at or supported by the National Institute of Allergy and Infectious Diseases and the Centers for Disease Control and Prevention, both of which are American institutions, have shown survival in aerosols for up to a few hours; on copper for up to a few hours; on cardboard for up to one day; and on plastic and stainless steel for up to a few days.
Concerning produce, as other pathogens can be found transiently on fruits and vegetables as a result of contamination, we should expect this to be true for COVID-19 as well, and we should wash and rinse our produce thoroughly. This means there should be no more tasting of grapes or cherries in the supermarket.
Q. There is lots of (mis-) information online about ways to kill the virus, particularly around heat and the use of saunas. Can you dispel some of those myths?
A. With a few exceptions possibly, cold temperatures do not kill viruses. Heat, on the other hand, definitely kills viruses, but the minimum temperature and exposure time to accomplish this vary from virus to virus.
Generally, 60-minute exposures to temperatures above 60 C kill most viruses, as would shorter exposures to higher temperatures. Nevertheless, using these moderate temperatures to try to eliminate viruses is not very practical.
Viruses are killed by a variety of disinfectants and by hand sanitizers that contain at least 60 per cent alcohol. In the process of proper hand-washing, employing soap and warm water, viruses are physically removed from the skin. Coronaviruses are actually killed because soap removes their membranous envelope that allows them to attach to host cells to initiate infection.
Q. Why and how does the virus make people sick (in lay terms)?
A. COVID-19 is a severe acute infection of the respiratory tract. A likely progression of the disease is as follows:
Upon entering the body, the virus establishes itself in the upper respiratory tract (nose and throat).
Around five to six days after exposure, the first symptoms occur, one or more of fever, dry cough, fatigue, aching muscles, sore throat and nasal congestion. In more serious cases the virus moves into the lower respiratory tract (the lungs) to cause a pneumonia that is indicated by shortness of breath.
The development of the disease is due to the ability of the virus to infect and kill cells that line the respiratory tract, including the air sacs in the lungs, and to an exaggerated response by the immune system that causes extreme inflammation in the lungs. This affects our ability to breathe.
Age and overall health are factors in the severity of the disease. Older adults and those with chronic diseases of the lungs and heart, for example, are most likely to experience serious disease, whereas healthy children are least likely.
An inspirational message is displayed in a window of a home in Sudbury on April 16.John Lappa/Sudbury Star
Q. What about treatment and prevention?
A. Treatment of a viral disease like COVID-19 requires administering an effective antiviral agent or administering antibodies that eliminate the virus. Antibodies are proteins produced by the immune system in response to infection, and for some diseases, they can be made available for therapeutic use.
Currently, neither type of therapy is available, but research and trials are in progress. The major preventative would be a vaccine and this is being pursued.
Q. Does this virus show much capacity for mutation? Should we be concerned about mutation?
A. The genome of a virus can be altered by a change in the base sequence, a process called mutation. It can also be altered by a process called genetic recombination, in which a second virus contributes some of its genome to another genome. Genetic recombination can happen if the two different viruses infect a host cell at the same time.
Mutations tend to cause minor changes in the characteristics of the virus, whereas genetic recombination can result in major changes. It is these major changes that can produce a new strain of the virus capable of causing a pandemic, as there is no immunity to the new strain. Given that coronaviruses have been shown to mutate and to undergo genetic recombination, and to move from one animal species to another, we should expect the same of the COVID-19 virus. This means, of course, that a disease similar to COVID-19 could emerge in the future.
Q. Once youve been sick, are you immune to the virus?
A. It is a reasonable assumption that individuals who have had the disease will have a substantial period of immunity, if not life-long immunity, to subsequent exposure to the same strain of the virus. Moreover, immunity as a result of having had a disease is superior to that acquired by any immunization procedure (vaccine), which should be true for COVID-19 as well.
Q. Can you predict how this virus will travel through the human population? Do you foresee a second/third/fourth wave of sickness?
A. It is difficult to predict virus movement through the population, but if we look at what has happened thus far in our province and in countries further into the pandemic we see that: older adults and individuals with certain chronic conditions get seriously ill; certain sites in a community, for example, long-term care facilities, can have high densities of infection; individuals who provide essential services are exposure-prone; and hospitals can be overwhelmed with patients needing intensive care.
Past influenza pandemics tell us there can be more than one wave of illness, each separated by a few months. Because the reasons for a second or even third wave are not always known in advance, it is difficult to predict waves. It is much easier to account for them after the fact.
Q. What are the best- and worst-case scenarios?
A The best-case scenario would be if our preventive measures had a major positive impact and terminated this outbreak within a few months. For this scenario, as for some others, there would be the issue of individuals at highest risk and without immunity emerging from isolation into a population where some might still be harboring COVID-19. The development of a vaccine or effective anti-viral medication would eliminate this as an issue.
The worst-case scenario would be to experience for an extended period of time what is currently happening in Italy, Spain and the USA.
Q. There has been media attention on the need to strip and change clothes when you come home. Is this necessary? What other measures, besides washing hands, maintaining distance and stifling coughs, should we be putting into practice?
A To protect ourselves, family members and others, it is important to adopt effective procedures and behaviours. As respiratory droplets discharged by infected persons travel in the air for a metre or so, maintain a safe space of two metres. Cough and sneeze into the bent arm or into a tissue. Avoid touching ones face to prevent introducing the virus into your body. Wash hands properly with soap and warm water, frequently and at critical times. Sanitize hands at critical times with sanitizer containing at least 60 per cent alcohol.
If you decide to wear a mask when you are in public, sanitize your hands before putting the mask on and just before and just after taking the mask off, and be aware the mask might collect infectious droplets. Do not use masks designed for health care workers because of their limited supply.
We should be aware that clothing can become contaminated if the two-metre barrier is broken and by contact with or transfer from surfaces and objects. Individuals should assess their own probability of exposure and that of their children, and decide if changing clothes is necessary.
The Public Health Sudbury and Districts website (phsd.ca) should be visited frequently and the recommendations for isolation and in-person socializing followed.
sud.editorial@sunmedia.caTwitter: @SudburyStar
Go here to read the rest:
Sudbury Accent: The best and worse case scenarios for COVID-19 - The Sudbury Star
- Podcast 9 Athens part 3 and news - November 8th, 2009 [November 8th, 2009]
- Podcast 10 Athens part 4 - November 8th, 2009 [November 8th, 2009]
- Podcast 11 Athens Part 5 - November 8th, 2009 [November 8th, 2009]
- Episode 12 Cardiac Nuclear Medicine in the UK - November 8th, 2009 [November 8th, 2009]
- Podcast 13 Choline PET and prostate cancer - November 8th, 2009 [November 8th, 2009]
- Episode14 ED function and Dysponea - November 8th, 2009 [November 8th, 2009]
- ep 15 Collimator Choice and Reconstruction algorithm - November 8th, 2009 [November 8th, 2009]
- Episode 16 Dr Strauss on vulnerable plaque - November 8th, 2009 [November 8th, 2009]
- Episode17 Chemical Stress - November 8th, 2009 [November 8th, 2009]
- Episode 18 Myocardial Perfusion Imaging and Diabetes - November 8th, 2009 [November 8th, 2009]
- Episode 19 The INSPIRE trial - November 8th, 2009 [November 8th, 2009]
- 20 Dual isotope with a difference - November 8th, 2009 [November 8th, 2009]
- Episode 21 The real effect of stress - November 8th, 2009 [November 8th, 2009]
- Episode 22 D-SPECT - November 8th, 2009 [November 8th, 2009]
- Episode 23 VQ Reprise - November 8th, 2009 [November 8th, 2009]
- Episode 24 Hepatobiliary Nuclear Medicine - November 8th, 2009 [November 8th, 2009]
- Episode 25 Sleep Apnea - November 8th, 2009 [November 8th, 2009]
- Episode 26 Imaging Post Traumatic Stress Disorder - November 8th, 2009 [November 8th, 2009]
- Episode 27 Cardiac Stem Cells - November 8th, 2009 [November 8th, 2009]
- Episode 28 Molly Supply - November 8th, 2009 [November 8th, 2009]
- Episode 29 Melanoma therapy interview with Dr Ekaterina Dadachova - November 8th, 2009 [November 8th, 2009]
- Episode 30 Viral Therapy - November 8th, 2009 [November 8th, 2009]
- Episode 31 breast radiotherapy using radioisotopes - November 8th, 2009 [November 8th, 2009]
- Episode 32 news from snm - November 8th, 2009 [November 8th, 2009]
- Episode 33 EBV Imaging and Therapy - November 8th, 2009 [November 8th, 2009]
- Episode 34 Dr Lele SNM India 2009 - December 14th, 2009 [December 14th, 2009]
- Episode 35 Dr Andrew Scott from the Ludwig institute - January 10th, 2010 [January 10th, 2010]
- Episode 36 CardiArc - February 25th, 2010 [February 25th, 2010]
- Episode 37 Dr Modder Radiosynoviorthesis (Radiation Synovectomy) - March 31st, 2010 [March 31st, 2010]
- Episode 38 Indian Nuclear Medicine With Dr Malhotra and Dr Krishna - May 28th, 2010 [May 28th, 2010]
- Episode 39 Prof Ora Israel The Utility of Hybrid Imaging - July 13th, 2010 [July 13th, 2010]
- Episode 40 New V/Q SPECT developments - October 11th, 2010 [October 11th, 2010]
- Episode 41 scintimun - February 14th, 2011 [February 14th, 2011]
- Episode 42 Radio-Isotope Supply into the future - March 6th, 2011 [March 6th, 2011]
- Podcast 4: DNA therapy - April 24th, 2011 [April 24th, 2011]
- Sorry about the delay a new podcast will be out soon! - April 24th, 2011 [April 24th, 2011]
- Podcast 5 Flash 3D - April 24th, 2011 [April 24th, 2011]
- Podcast 6 Affibody - April 24th, 2011 [April 24th, 2011]
- Podcast 7 EANM 2006 Athens Part 1 - April 24th, 2011 [April 24th, 2011]
- Podcast 8 Athens Part 2 - April 24th, 2011 [April 24th, 2011]
- Episode 43 Rapidscan Part 1, 720P high quality video version - May 1st, 2011 [May 1st, 2011]
- Episode 43 Rapidscan Part 1, Ipod quality video - May 1st, 2011 [May 1st, 2011]
- Episode 43 Rapidscan Part 1, Audio version - May 1st, 2011 [May 1st, 2011]
- Episode 45 Mummies with cardiovascular disease video - May 21st, 2011 [May 21st, 2011]
- Episode 45 Mummies with cardiovascular disease audio edition - May 21st, 2011 [May 21st, 2011]
- Episode 46 Dr Gordon DePuey Choosing Reconstruction clinical perspective - August 7th, 2011 [August 7th, 2011]
- Episode 46 Dr Gordon DePuey Choosing Reconstruction clinical perspective audio version - August 7th, 2011 [August 7th, 2011]
- Episode 47 Cardiac Image Fusion With Dr Kaufmann - September 18th, 2011 [September 18th, 2011]
- Episode 47 Cardiac Fusion with Dr Kaufmann video version - September 18th, 2011 [September 18th, 2011]
- Dear Steve, I am and many more like me are your one more thing. - October 9th, 2011 [October 9th, 2011]
- EPISODE 48 PET MRI camera from Siemens with Dr Georgi audio - October 23rd, 2011 [October 23rd, 2011]
- EPISODE 48 PET MRI camera from Siemens Dr Georgi video - October 23rd, 2011 [October 23rd, 2011]
- Silicon Biosystems to Present Single-Circulating Tumor Cell Molecular Characterization at the Fourth World CTC Summit - April 25th, 2012 [April 25th, 2012]
- Leukaemia cells have a remembrance of things past - April 25th, 2012 [April 25th, 2012]
- Technologist Education Requirements Can Help Cut Repeat Scans - April 25th, 2012 [April 25th, 2012]
- HKU Collaborative Research Discovers A Novel Molecular Mechanism Of A New Anti-HIV-1 Drug Candidate - April 25th, 2012 [April 25th, 2012]
- Focal Segmental Glomerulosclerosis and the Nephrotic Syndrome - Part 1 Clinical - Video - May 4th, 2012 [May 4th, 2012]
- Electro-Medicine : Biological Physics - The Molecular Basis of Alzheimers Disease - Video - May 4th, 2012 [May 4th, 2012]
- osdd heterocyclic compounds and molecular medicines - Video - May 4th, 2012 [May 4th, 2012]
- Molecule to Medicine: The Biomarker Frontier - Video - May 4th, 2012 [May 4th, 2012]
- Fulfilling the Promise of Molecular Medicine in a Developmental Brain Disorder - Video - May 4th, 2012 [May 4th, 2012]
- Focus on Stefanie Dimmeler - Video - May 4th, 2012 [May 4th, 2012]
- Dundee - May 4th, 2012 [May 4th, 2012]
- Nanotechnology In Medicine: Huge Potential, But What Are The Risks? - May 5th, 2012 [May 5th, 2012]
- Cutting Edge Technology Coming To DMH - May 5th, 2012 [May 5th, 2012]
- This Week in Experimental and Molecular Pathology - May 5th, 2012 [May 5th, 2012]
- Researchers' discovery offers hope for cancer, heart disease miracle drugs - May 7th, 2012 [May 7th, 2012]
- Penn State student Zachary Hostetler from Garnet Valley is being honored as a student marshal - May 7th, 2012 [May 7th, 2012]
- NCKU Student Wins Prestigious Award for Anti-Cancer Research - May 10th, 2012 [May 10th, 2012]
- In-Vitro Diagnostics (IVD) Market (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology Analyzers ... - May 10th, 2012 [May 10th, 2012]
- Pitt team uses genomics to identify a molecular-based treatment for a viral skin cancer - May 10th, 2012 [May 10th, 2012]
- Genomics used to identify a molecular-based treatment for a viral skin cancer - May 10th, 2012 [May 10th, 2012]
- 2 molecular biologists get $500K medical prize - May 13th, 2012 [May 13th, 2012]
- 2 molecular biologists share $500K medical prize - May 13th, 2012 [May 13th, 2012]
- Lab21 Unveils New Molecular Analysis Services at Greenville Site - May 13th, 2012 [May 13th, 2012]
- 2 molecular biologists from NYC to share $500K medical prize for pioneering research on cells - May 13th, 2012 [May 13th, 2012]
- Two Molecular Biologists Get $500K Medical Prize - May 13th, 2012 [May 13th, 2012]
- Pair of molecular biologists receive Albany Medical Center Prize - May 13th, 2012 [May 13th, 2012]
- CNIO scientists successfully test the first gene therapy against aging-associated decline - May 16th, 2012 [May 16th, 2012]
- Cancer Institute of New Jersey Aims to Advance Personalized Cancer Treatments Through 'Precision Medicine' - May 16th, 2012 [May 16th, 2012]